Development of a Point-of-Care Mass Spectrometry Analysis System

描述(由申请人提供)：我们建议开发一种质谱仪(MS)分析系统和一种可应用于医疗诊断的护理点(POC)化学分析的方案。其目标是开发(1)体积紧凑、拥有和维护成本低但具有足够定量分析性能的微型质谱仪，(2)用于直接分析血液样本的样品盒，以及(3)允许护士和医生使用该系统的操作规程，他们不需要使用MS进行特殊的化学分析培训。普渡大学的研究团队一直在推动技术和应用的开发，使MS分析能够用于临床现场的POC测试，并最终用于个人健康护理。我们的长期目标是开发POC MS系统，并与德克萨斯大学MD Anderson癌症中心(UTMDACC)等研究人员合作，验证该技术，并将其纳入药物开发，以优化疾病治疗。已确定POC-MS系统开发中的关键问题是整个分析系统的小型化和分析方案的简化。在这个R01项目中，我们 建议开发一套完整的基于微型离子陷阱和纸张喷雾技术的POC MS分析系统和相关操作规程，并验证该系统用于肿瘤药物治疗药物监测。拟议工作的预期结果是产生第一个POC MS系统，具有相对完整的治疗药物监测解决方案，并可能对基于MS的临床诊断化学分析系统的未来发展产生重大影响。

DESCRIPTION (provided by applicant): We propose to develop a mass spectrometry (MS) analysis system and a protocol that can be applied for chemical analysis at the point of care (POC) for medical diagnosis. The aims are to develop (1) a miniature mass spectrometer that has compact size, low cost of ownership and maintenance but with adequate performance for quantitative analysis, and (2) sample cartridges for direct analysis of blood samples and (3) an operational protocol that allows this system to be used by nurses and physicians, who do not need to have special training in chemical analysis using MS. This research team at Purdue University has been consistently pushing the development of technologies and applications to allow MS analysis to be used for POC tests at clinical sites and ultimately for personal health care. Our long term goal is to develop a POC MS system and collaborate with researchers such as those at The University of Texas MD Anderson Cancer Center (UTMDACC) to validate the technology and to incorporate it into drug development to optimize disease therapy. The critical issues in the development of a POC MS system have been identified as the miniaturization of the entire analysis system and the simplification of the analysis protocol. In this R01 project, we propose to develop a complete POC MS analysis system and associated operational protocol based on miniature ion trap and paper spray technologies, and to validate the system for therapeutic drug monitoring with oncology drugs. The expected outcome from the proposed work is the generation of the first POC MS system with a relatively complete solution for therapeutic drug monitoring and with potential for a significant impact on future development of MS-based chemical analysis systems for clinical diagnosis.